GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Virtual Healthcare Conference on Monday, November 15 and the Jefferies London Healthcare Conference on Wednesday, November 17. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:

Stifel 2020 Virtual Healthcare Conference

November 15-17, 2021

GlycoMimetics presentation: Monday, November 15, 3:20 p.m. (ET)

Jefferies London Healthcare Conference

November 16-19, 2021

GlycoMimetics presentation: Wednesday, November 17, 11:20 AM GMT (6:20 AM ET)

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006046/en/